These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15837456)

  • 1. How much do we have to pay for how many interim analyses?
    Koch A
    Contemp Clin Trials; 2005 Feb; 26(1):113-6. PubMed ID: 15837456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The use of state of the art statistical methodology in biomedical research: the example of methodology for interim analyses in clinical trials].
    Muñoz SR; Bangdiwala SI
    Rev Med Chil; 2001 Sep; 129(9):983-8. PubMed ID: 11725478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interim analysis in clinical trials: a methodological guide].
    Muñoz Navarro SR; Bangdiwala SI
    Rev Med Chil; 2000 Aug; 128(8):935-41. PubMed ID: 11129556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sequential analysis in clinical and epidemiological research].
    van der Tweel I; Schipper M
    Ned Tijdschr Geneeskd; 2002 Dec; 146(49):2348-52. PubMed ID: 12510397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials.
    Stone A
    Pharm Stat; 2010; 9(2):151-61. PubMed ID: 19771540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methodological deficiencies in clinical trials].
    Nahler G
    Fortschr Med; 1992 Oct; 110(28):511-4. PubMed ID: 1398408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some optimal and non-optimal two-stage designs using an alpha-spending function.
    Patel HI
    Stat Med; 1996 Aug; 15(16):1739-45. PubMed ID: 8870156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interim analysis in therapeutic trials: a brief survey of current developments].
    Falissard B; Lellouch J
    Rev Epidemiol Sante Publique; 1991; 39(4):365-72. PubMed ID: 1754702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comment on interim analyses in crossover trials.
    Grieve AP; Senn S
    Biometrics; 1996 Dec; 52(4):1515-20. PubMed ID: 9019232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
    Lai TL; Shih MC; Zhu G
    Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biostatistical issues].
    Hudec M
    Onkologie; 2008; 31 Suppl 2():14-20. PubMed ID: 18487863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.